2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriers
2020
Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study
Joudrey PJ, Chadi N, Roy P, Morford KL, Bach P, Kimmel S, Wang EA, Calcaterra SL. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug And Alcohol Dependence 2020, 211: 107968. PMID: 32268248, PMCID: PMC7529685, DOI: 10.1016/j.drugalcdep.2020.107968.Peer-Reviewed Original ResearchOpioid treatment programsMethadone accessOpioid use disorderCross-sectional studyOpioid overdose deathsCensus tractsDrive timeRural census tractsMethadone treatmentOverdose deathsUse disordersLong drive timesMethadoneTreatment programChain pharmaciesTractMedian differenceRural censusHigh ratePharmacyMedianUnited StatesPopulation